BI/Lilly's Jardiance Takes On AstraZeneca's Farxiga With Heart Failure Approval
Blockbuster Gets EU Green Light For HFrEF
Cardiologists in Europe who have so far been unwilling to embrace the SGLT2 class now have two drugs approved for heart failure with reduced ejection fraction, with Jardiance soon to join Farxiga on the market, potentially attractive options especially for their diabetic patients.
You may also be interested in...
Boehringer Ingelheim’s cardiometabolism head Mohamed Eid considers the impact of EMPEROR-Preserved study on the heart failure treatment landscape and looks ahead at potential new conquests in kidney disease for its SGLT2 inhibitor.
The full dataset from the closely-watched study demonstrated that Jardiance showed a 21% reduction in the risk of cardiovascular death or hospitalization for HFpEF compared with placebo, a significantly greater benefit than seen with the only approved drug for the indication, Novartis's Entresto.
A Phase III trial in heart failure with preserved ejection fraction showed a benefit, which could result in a broad heart failure label for the SGLT2 inhibitor.